Skip to content

OS Therapies OSTX Accrued Expenses

Accrued Expenses at other companies

Immunome logo
ImmunomeIMNM
$21.88M+23.9%
CTO
Citius Oncology, Inc.CTOR
$4.06M-53.4%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$1.75M-1.0%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$19M+11.8%
WHW
Whitehawk Therapeutics, Inc. Common StockWHWK
$9.31M+8.1%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K
Free cash flow-$3.7M

Valuation

See full
Market cap$84.62M+65.5%
Enterprise value$103.7M

Returns & leverage

See full
Return on equity470%
Debt / equity-1.8×
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's accrued expenses?
OS Therapies (OSTX) reported accrued expenses of $1.38M in Q1 2026.
How has OS Therapies's accrued expenses changed year-over-year?
OS Therapies's accrued expenses increased by 278.5% year-over-year, from $364.41K to $1.38M.
What is the long-term trend for OS Therapies's accrued expenses?
Over 2 years (2023 to 2025), OS Therapies's accrued expenses has grown at a 191.3% compound annual growth rate (CAGR), from $162.5K to $1.38M.
What does accrued expenses mean?
Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.